Pall eBDS: Bacteria Detection for Platelets
User Benefits
A Complete Turnkey System
- Pall provides all the necessary components for testing and data logging results:
- Pall eBDS oxygen analyzer with bar code scanner.
- Helmer incubator and agitator (various sizes available).
- Sampling stand.
- Pall Data (data management software).
Unsurpassed Sensitivity and Specificity
- Ten organisms were selected for determining the performance characteristics of the Pall eBDS:
- 96.6% of all samples tested for bacteria immediately after inoculation and sampling tested positive when sampling occurred immediately following inoculation. See Table 1 below.
- 100% of all samples tested positive when sampling occurred after a 24-hour incubation at room temperature. See Table 2 below.
- No false positives were detected in the control samples. [Field data reported to date has shown an average false positive rate of 1/1,554 (0.064%), and a true positive rate of approximately 1/5,100 (0.02%).]
Single Point Detection Provides Test of Record Prior to Transfusion
- Pall eBDS provides a clear pass/fail readout for each unit tested, and establishes a test of record.
- No further monitoring of the unit is necessary once test is complete.
Easy to Use with Minimal Platelet Loss
- Pall eBDS has been designed to support blood bank cGMP, and easily integrates into routine practice.
- A single use, closed system designed to minimize false positives from outside contaminants.
- Rapid read system provides pass/fail results in approximately 30 seconds. No interpretation is necessary.
- Minimal platelet loss of approximately 4 mL per sample.
Top
Performance Summary for the Pall eBDS: Simple, Sensitive, Seamless
Sensitive*
Table 1 illustrates that 96.6% of all samples tested positive when sampling occurred immediately following inoculation.
Table 2 illustrates that 100% of all samples tested positive when sampling occurred after a 24-hour incubation at room temperature.
Specific
No false positives were detected in the control samples.
1. Lee JH. In: Bacterial Contamination of Platelets Workshop, Bethesda, September 24, 1999. (Cited May 3, 2000.) Available from http://www.fda.gov/cber/minutes/bact092499.pdf
* Sensitivity varies depending on the bioburden and duration of incubation prior to sampling.
Table 1. Performance Summary with Sampling Taken at the Time of Inoculation
Bacteria Level Immediately After Inoculation and Sampling
(Sample Time = 0 hrs)Number Detected out of Total Tested
< 5 CFU/mL
6-15 CFU/mL
16-50 CFU/mL
> 51 CFU/mL
(Detection with sampling at 0 hrs)
S. epidermidis
4
1
5 of 5
S. agalactiae
5
4
2
11 of 11
S. aureus
5
4
9 of 9
P. aeruginosa
11
8 of 11
S. choleraesuis
4
2
5
11 of 11
E. coli
1
6
7 of 7
E. cloacae
6
6 of 6
B. cereus
2
6
4
12 of 12
K. pneumoniae
3
7
1
11 of 11
S. marcescens
5
5 of 5
TOTAL
19
53
16
0
85 of 88 (96.6%)
Table 2. Performance Summary with Sampling Taken 24 Hours After Inoculation
(Number of Bacteria Detected with 24 Hour Incubation)
|
Bacteria Level at the Time of Inoculation |
Bacteria Level After 24 Hours Storage (Sample Time = 24 hrs) | Number Detected out of Total Tested | ||||
|---|---|---|---|---|---|---|
|
Median (range) |
< 5 CFU/mL | 6-15 CFU/mL | 16-50 CFU/mL | > 51 CFU/mL | (Detection with sampling at 24 hrs) | |
| S. epidermidis | 7 (2-52) | 1 | 15 | 8 | 3 | 27 of 27 |
| S. agalactiae | 5 (2-20) | 3 | 7 | 9 | 9 | 28 of 28 |
| S. aureus | 8 (2-51) | 5 | 24 | 29 of 29 | ||
| P. aeruginosa | 9 (1-15) | 1 | 4 | 19 | 24 of 24 | |
| S. choleraesuis | 8 (1-55) | 6 | 2 | 16 | 24 of 24 | |
| E. coli | 6 (2-15) | 27 | 27 of 27 | |||
| E. cloacae | 8 (2-13) | 4 | 4 | 4 | 16 | 28 of 28 |
| B. cereus | 13 (3-27) | 2 | 31 | 33 of 33 | ||
| K. pneumoniae | 5 (1-17) | 12 | 9 | 3 | 9 | 33 of 33 |
| S. marcescens | 9 (1-16) | 2 | 25 | 27 of 27 | ||
| TOTAL | 28 | 36 | 37 | 179 | 280 of 280 (100%) | |
Top
The Testing Principle and System Components
Percent Oxygen in Air, the Practical Approach
The Pall eBDS novel approach to detection measures the oxygen content of air within the sample pouch as a surrogate marker for bacteria. The Pall eBDS Oxygen Analyzer is used to measure the percent of oxygen in the headspace gas of the sample pouch. If bacteria are present in the platelet sample collected, an increasing amount of oxygen is consumed through the metabolic activity and proliferation of the bacteria in the sample during incubation, resulting in a measurable decrease in oxygen content of the plasma as well as the air within the sample pouch.
Pall eBDS Sample Set
Enhances bacteria recovery and improves oxygen sampling.
Incubator and Agitator
Pall eBDS Oxygen Analyzer
|
![]() ![]() |
Pall Data
A software package that captures the output from the Pall eBDS Oxygen Analyzer and allows the information to be queried into a user-defined report. Learn more.
Top
Detect Bacteria in Platelets with Confidence: Steps to Using Pall eBDS
- Sterile connect the Pall eBDS Sample Set to the platelet product. Refer to Performance Data for optimal sampling time.
- Fill sample pouch with approximately 3 mL of platelet product.
- Disconnect the sample pouch from the Pall eBDS Sample Set and incubate pouch at 35 °C for 24 to 30 hours.
- At the desired time following incubation, measure the oxygen content in the air above the plasma in the sample pouch using the Pall eBDS Oxygen Analyzer.
- The LED display on the oxygen analyzer will then read either "Pass" or "FAIL".
- Results are captured electronically and a report can be printed or exported.
Top
Training and Implementation
Top
Complementary Products
Using a platform of complementary products, blood collection facilities are able to produce a therapeutic dose of platelets that are pooled, leukoreduced, ABO matched, and bacteria tested with culture based detection methods – in other words, an Acrodose Platelet. Read more about:
- An AcrodoseSM Platelet
- Collecting and Processing: Leukotrap® RC PL and Leukotrap PL Systems
- Pooling and Storing: Acrodose™ PL System
For the full story, go to A New Platform for Platelet Transfusion Safety.
Top


The total solution for detection of bacteria for quality control testing in leukocyte-reduced apheresis platelets and whole blood derived platelets in plasma





